Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q3 2020 · 10-Q
Revenue$13.37K$13.37K−68.1% vs Q3 2019 Net Income$587.77K$587.77KN/M vs Q3 2019 EPS Diluted$0.00$0.00— vs Q3 2019 Gross Profit$10,266−71.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$137,054N/M Margins · derivedGross margin76.8%−7.7 pt vs Q3 2019
Operating margin-1396.6%−836.1 pt vs Q3 2019
Net margin4395.5%+5556.3 pt vs Q3 2019
ended Sep 30, 2020 · filed Aug 12, 2021 · 316 d after period end